Who are Teriparatide Pen Injector's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Parathyroid Hormone (PTH), teriparatide and alendronate, rhPTH (1-84), Teriparatide (Forteo), Teriparatide (rDNA origin), FORSTEO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teriparatide-pen-injector.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Teriparatide Pen Injector — Competitive Intelligence Brief

Teriparatide Pen Injector (Teriparatide Pen Injector) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parathyroid hormone analog. Area: Endocrinology / Bone Metabolism.

marketed Parathyroid hormone analog PTH1 receptor Endocrinology / Bone Metabolism Small molecule Live · refreshed every 30 min

Target snapshot

Teriparatide Pen Injector (Teriparatide Pen Injector) — University of Edinburgh. Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Teriparatide Pen Injector TARGET	Teriparatide Pen Injector	University of Edinburgh	marketed	Parathyroid hormone analog	PTH1 receptor
Parathyroid Hormone (PTH)	Parathyroid Hormone (PTH)	Takeda	marketed	Peptide hormone / PTH1 receptor agonist	PTH1 receptor (PTHR1)
teriparatide and alendronate	teriparatide and alendronate	Medical University of Vienna	marketed	Combination therapy: PTH analog + bisphosphonate	PTH1 receptor (teriparatide); farnesyl pyrophosphate synthase (alendronate)
rhPTH (1-84)	rhPTH (1-84)	Shire	marketed	PTH1 receptor agonist	PTH1 receptor
Teriparatide (Forteo)	Teriparatide (Forteo)	M.D. Anderson Cancer Center	marketed	Parathyroid hormone analog	PTH1 receptor (parathyroid hormone 1 receptor)
Teriparatide (rDNA origin)	Teriparatide (rDNA origin)	Bio Sidus SA	marketed	Parathyroid hormone analog	PTH1 receptor (PTHR1)
FORSTEO	FORSTEO	Shenzhen Salubris Pharmaceuticals Co., Ltd.	marketed	Parathyroid hormone analog	PTH1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parathyroid hormone analog class)

Bio Sidus SA · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Pfenex, Inc · 1 drug in this class
Shenzhen Salubris Pharmaceuticals Co., Ltd. · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teriparatide Pen Injector — Competitive Intelligence Brief. https://druglandscape.com/ci/teriparatide-pen-injector. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab